Misonix completed the acquisition of Solys Medical.
Four things to know:
1. The acquisition was an all-stock transaction of roughly $109 million in value on the date prior to closing.
2. In the deal, Misonix acquired TheraSkin, Solys Medical's cellular and tissue-based wound treatment.
3. The acquisition consisted of the issuance of around 5.7 million new shares to former Solys unitholders.
4. Misonix assumed Solsys' outstanding secured debt of roughly $24 million.
More articles on devices:
Dr. Isaac Karikari: Changing attitudes toward opioids and how physicians can drive change
Dr. Timothy Kremchek to operate on Reds rookie Nick Senzel — 4 insights
Icotec to introduce new pedicle screw system — 4 insights